90.7% of participants taking semaglutide 7.2 mg achieved a body weight reduction of greater than or equal to 5%, compared to 89.9% and 36.8% for semaglutide 2.4 mg and placebo, respectively
Although cholecystitis has been reported, large outcome trials have not substantiated pancreatitis signals, and current evidence does not indicate increased risks of infection or obesity-related cancers
It is not approved for human or veterinary use , and may not be used in food, drugs, diagnostic procedures, or cosmetics
Several FDA-approved medications for weight management operate through entirely different pathways, and for some people, these options work better than GLP-1 agonists
However, an evaluation of the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2020 found a significantly increased (proportional reporting ratio: 9.86) pancreatic cancer cases associated with GLP1 RAs compared to the other glucoselowering agents analysed in the study [22]
Five participants were prescribed GLP-1 receptor agonists for obesity management